Acesso livre
Acesso livre

Saúde Pública/Medicina Humanitária

Medicamento da Merck contra COVID perde seu brilho: o que isso significa para a pandemia – “Molnupiravir foi inicialmente anunciado pelos oficiais de saúde pública como um elemento que mudaria o cenário da COVID-19, mas dados finais dos estudos clínicos mostraram eficácia abaixo das expectativas.”

16 Dez, 2021 | 13:04h

Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature

Conteúdos relacionados:

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Opinião | Cobertura vacinal desigual no mundo é o centro da atual crise da Covid-19.

16 Dez, 2021 | 13:02h

Unequal global vaccine coverage is at the heart of the current covid-19 crisis – The BMJ

Segurança no aborto com o uso de mifepristona no Canadá.

16 Dez, 2021 | 12:51h

Abortion Safety and Use with Normally Prescribed Mifepristone in Canada – New England Journal of Medicine

Comunicado de imprensa: Prescribing the abortion pill without restrictions is safe and effective, study finds – University of British Columbia

Opinião | Tomadores de decisão precisam constantemente de síntese de evidência atualizada.

16 Dez, 2021 | 12:41h

Decision makers need constantly updated evidence synthesis – Nature

M-A | Porcentagem global de infecções assintomáticas por SARS-CoV-2 é em torno de 40%.

15 Dez, 2021 | 12:48h

Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis: A Systematic Review and Meta-analysis – JAMA Network Open

Comentário: ~40 Percent With Confirmed COVID-19 Are Asymptomatic – HealthDay

[Comunicado de imprensa – ainda não publicado] Em análise final, pílula da Pfizer contra Covid mantém a eficácia de 89% em reduzir o risco de internação ou morte.

15 Dez, 2021 | 12:47h

Comunicado de imprensa: Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel Covid-19 oral antiviral treatment candidate in reducing risk of hospitalization or death

Comentários:

Pfizer’s Covid pill remains 89% effective in final analysis, company says – STAT

Pfizer confirms COVID pill’s results, potency versus omicron – Associated Press

Conteúdos relacionados:

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

 

Comentário no Twitter (fio – clique para saber mais)

 

Riscos de miocardite, pericardite e arritmias cardíacas associadas à vacinação contra COVID-19 vs. infecção por SARS-CoV-2.

15 Dez, 2021 | 12:45h

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection – Nature Medicine

Comunicado de imprensa: COVID-19 infection, more likely than vaccines, to cause rare cardiovascular complications – University of Oxford

 

Comentários no Twitter

 

Estudo sugere que os comprovantes de vacinação contra COVID-19 podem reforçar a imunização em países com cobertura vacinal abaixo da média.

15 Dez, 2021 | 12:43h

Comunicado de imprensa: COVID-19 certificates may boost vaccine uptake in countries with below average coverage – University of Oxford

Estudo original: The effect of mandatory COVID-19 certificates on vaccine uptake: synthetic-control modelling of six countries – The Lancet Public Health

 

Comentário no Twitter

 

De disseminação rápida, a variante Ômicron está atualmente em 77 países e a OMS adverte contra presumir que seus efeitos sejam leves.

15 Dez, 2021 | 12:42h

Rapidly Spreading Omicron is Now in 77 Countries and WHO Warns Against Assuming its Effects are Mild – Health Policy Watch

[Ainda não publicado] Dados iniciais da África do Sul mostram que, diante de infecção pela variante Ômicron, a proteção vacinal pode cair a 30%, mas ainda impede a doença grave.

15 Dez, 2021 | 12:40h

Vaccine protection vs. omicron infection may drop to 30% but does cut severe disease – NPR

Ver também: South Africa Omicron study finds drop in vaccine protection, fewer hospitalized – CIDRAP

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.